AngioDynamics (ANGO) Misses Q3 EPS by 3c, Revenues Miss; Reiterates FY19 EPS/Revenue Mid-Point Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
KeyBanc Upgrades AngioDynamics (ANGO) to Overweight
April 1, 2019 2:06 PM EDTKeyBanc analyst Matthew Mishan upgraded AngioDynamics (NASDAQ: ANGO) from Sector Weight to Overweight with a price target of $33.00.
For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.
Shares of AngioDynamics closed at $22.86 yesterday.
... MoreAngioDynamics (ANGO) Granted FDA Approval to Begin NanoKnife DIRECT Clinical Study for Treatment of Stage III Pancreatic Cancer
April 1, 2019 6:09 AM EDTAngioDynamics, Inc. (NASDAQ: ANGO) today announced that the United States Food and Drug Administration (FDA) approved the Companys investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation Direct IRE Cancer Treatment clinical study (DIRECT).
The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. In January 2018, the FDA granted the Companys NanoKnife System a Breakthrough Device Designation under the 21st... More
